HRC Ledger

Microfluidic isolation and molecular analysis of circulating tumor cells for the study of neuroendocrine transdifferentiation in prostate cancer

NewadministrativeOpportunity

Source: Nih-reporter ·

Microfluidic isolation and molecular analysis of circulating tumor cells for the study of neuroendocrine transdifferentiation in prostate cancer — MASSACHUSETTS GENERAL HOSPITAL

Build pursuit package

Key dates

Award date
August 7, 2026
Performance start
April 1, 2022
Performance end
March 31, 2027

Details

Buyer
National Cancer Institute
Agency
National Cancer Institute
Buyer type
Federal
Jurisdiction
Massachusetts (MA)
Category
Administrative
Value
$629,106
Set-aside
NAICS
PSC
Source
nih-reporter

Who is this buyer

National Cancer Institute

Organization

Source: Provider universe

Not matched to a provider record yet.

Buying history

Source: Solicitation records
  • Records49 total
  • Opportunities / awards0 / 0
  • Value range$9,890 – $1,258,345
  • ActiveAugust 11, 2026 – August 11, 2026

What they buy

  • Administrative (41)
  • Clinical (8)

Financial highlights

Source: IRS Form 990

No 990 filing on record.

Who holds their work today

Source: Solicitation records · awards

No awards on record for this buyer.

What they're trying to solve

Source: AI-generated

No brief written for this buyer yet.

Also open from this buyer

Source: Solicitation records

No other open opportunities on record.

Ways to meet this buyer

Source: Solicitation records · event notices

Upcoming

No upcoming events on record.

View source document →

Source link on nih-reporter.

← Back to all contracts